Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States

Clinical Infectious Diseases

Volumn 59, Issue 2, 2014, Pages 186-192

  Lippincott, Christopher K ^a   Miller, Melissa B ^b   Popowitch, Elena B ^a   Hanrahan, Colleen F ^c   Van Rie, Annelies ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

infection control

Indexed keywords

ADULT; ARTICLE; BACTERIUM ISOLATION; CLINICAL DECISION MAKING; COHORT ANALYSIS; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; THORAX RADIOGRAPHY; TRACHEAL ASPIRATION PROCEDURE; TUBERCULIN TEST; TUBERCULOSIS RAPID TEST; ADOLESCENT; AGED; COMPARATIVE STUDY; EVALUATION STUDY; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MICROSCOPY; MIDDLE AGED; MOLECULAR DIAGNOSIS; PATIENT CARE; PROCEDURES; SPUTUM; TIME; TUBERCULOSIS, PULMONARY; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIOLOGICAL TECHNIQUES; COHORT STUDIES; FEMALE; HUMANS; MALE; MICROSCOPY; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; PATIENT ISOLATION; SENSITIVITY AND SPECIFICITY; SPUTUM; TIME FACTORS; TUBERCULOSIS, PULMONARY; UNITED STATES; YOUNG ADULT;

EID: 84903948832     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu212     Document Type: Article

References (30)

1. Dowdle WR. A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1989; 38(suppl 3):1-25.
2. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2012. Atlanta, GA: US Department of Health and Human Services, 2013.
3. Jensen PA, Lambert LA, Iademarco MF, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54:1-141.
4. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: A systematic review. Lancet Infect Dis. 2006; 6:570-81. (Pubitemid 44262344)
5. Mathew P, Kuo YH, Vazirani B, Eng RH,Weinstein MP. Are three sputum acid-fast bacillus smears necessary for discontinuing tuberculosis isolation? J Clin Microbiol 2002; 40:3482-4. (Pubitemid 34977473)
6. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smearnegative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: Informing urgent policy changes. Lancet 2007; 369:2042-9. (Pubitemid 46908825)
7. Steingart KR, Ramsay A, Pai M. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert Rev Anti Infect Ther 2007; 5:327-31. (Pubitemid 47050155)
8. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161(4 pt 1):1376-95.
9. Watterson SA, Drobniewski FA. Modern laboratory diagnosis of mycobacterial infections. J Clin Pathol 2000; 53:727-32.
10. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. Geneva, Switzerland: WHO, 2011.
11. US Food and Drug Administration. FDA permits marketing of first U.S. test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin. Silver Spring, MD: FDA, 2013.
12. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-15.
13. Steingart KR, Sohn H, Schiller I, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013;1:CD009593.
14. Valenza G, Tappe D, Turnwald D, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008; 7:123-7. (Pubitemid 351372763)
15. Centers for Disease Control and Prevention. Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use-United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:821-4.
16. Marks SM, Cronin W, Venkatappa T, et al. The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States. Clin Infect Dis. 2013; 57:532-42.
17. World Health Organization. WHO monitoring of Xpert MTB/RIF rollout. Available at: Http://www.who.int/tb/laboratory/mtbrifrollout/en/. Accessed February 2014.
18. Thomas BS, Bello EF, Seto TB. Prevalence and predictors of compliance with discontinuation of airborne isolation in patients with suspected pulmonary tuberculosis. Infect Control Hosp Epidemiol 2013; 34:967-72.
19. Leonard MK, Egan KB, Kourbatova E, et al. Increased efficiency in evaluating patients with suspected tuberculosis by use of a dedicated airborne infection isolation unit. Am J Infect Control 2006; 34:69-72. (Pubitemid 43254573)
20. Harris AD, Pineles L, Belton B, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: A randomized trial. JAMA 2013; 310:1571-80.
21. Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA 2003; 290:1899-905. (Pubitemid 37430607)
22. Abad C, Fearday A, Safdar N. Adverse effects of isolation in hospitalised patients: A systematic review. J Hosp Infect 2010; 76:97-102.
23. Vinski J, Bertin M, Sun Z, et al. Impact of isolation on hospital consumer assessment of healthcare providers and systems scores: Is isolation isolating? Infect Control Hosp Epidemiol 2012; 33:513-6.
24. Shah NS, Cavanaugh JS, Pratt R, et al. Epidemiology of smear-negative pulmonary tuberculosis in the United States, 1993-2008. Int J Tuberc Lung Dis. 2012; 16:1234-40.
25. Sohn H, Aero AD, Menzies D, et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: Limitations in accuracy and clinical impact. Clin Infect Dis. 2014; 58:970-6.
26. Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: A systematic review. Int J Tuberc Lung Dis. 2007; 11:485-95. (Pubitemid 46732633)
27. Lee HY, Seong MW, Park SS, et al. Diagnostic accuracy of Xpert(R) MTB/RIF on bronchoscopy specimens in patients with suspected pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013; 17:917-21.
28. Theron G, Peter J, Meldau R, et al. Accuracy and impact of Xpert MTB/ RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 2013; 68:1043-51.
29. Miller MB, Popowitch EB, Backlund MG, Ager EP. Performance of Xpert MTB/RIF RUO assay and IS6110 real-time PCR for Mycobacterium tuberculosis detection in clinical samples. J Clin Microbiol 2011; 49:3458-62.
30. Choi HW, Miele K, Dowdy D, Shah M. Cost-effectiveness of Xpert(R) MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis. 2013; 17:1328-35.